Artificial intelligence (AI) software developer Neosoma has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Neosoma HGG, an AI application for assessing high-grade glioma (HGG) on brain MRI exams.
The software performs tumor segmentation and volumetric measurements, as well as generates imaging for 3D geometric analysis and longitudinal tracking of patients with high-grade glioma brain tumors, according to the vendor. These results can be used by physicians to plan procedures, evaluate postprocedural results, and guide chemotherapy and immunotherapy treatments, Neosoma said.
